We are live on
!
Find out more
HPG
Harvest Portfolios Group Portfolio holdings
AUM
$6.06B
1-Year Est. Return
16.63%
This Fund
S&P 500
This Quarter
Est. Return
+12.07%
1 Year Est. Return
+16.63%
3 Year Est. Return
+50.33%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
–
Cap. Flow
+$1.71B
Cap. Flow
% of AUM
98.49%
Top 10 Holdings %
Top 10 Hldgs %
29.01%
Holding
178
New
178
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$59.9M |
| 2 |
UnitedHealth
UNH
|
+$57.4M |
| 3 |
Zoetis
ZTS
|
+$49.7M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$46.1M |
| 5 |
AbbVie
ABBV
|
+$45.9M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.59% |
| 2 | Technology | 16.36% |
| 3 | Financials | 7.94% |
| 4 | Consumer Discretionary | 5.78% |
| 5 | Communication Services | 4.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Johnson & Johnson
JNJ
$625B
| $61.2M | 3.52% |
+346,707
| New | +$59.9M |
|
|
2
UnitedHealth
UNH
$370B
| $57.4M | 3.3% |
+108,275
| New | +$57.4M |
|
|
3
Zoetis
ZTS
$30B
| $49.2M | 2.83% |
+335,987
| New | +$49.7M |
|
4
AstraZeneca
AZN
$250B
| $48.7M | 2.8% |
+359,097
| New | +$45M |
|
5
Merck
MRK
$318B
| $48.6M | 2.79% |
+437,740
| New | +$44.7M |
|
|
6
AbbVie
ABBV
$435B
| $48.3M | 2.78% |
+299,120
| New | +$45.9M |
|
|
7
Thermo Fisher Scientific
TMO
$220B
| $47.9M | 2.75% |
+86,909
| New | +$46.1M |
|
8
Abbott
ABT
$187B
| $47.8M | 2.75% |
+435,715
| New | +$45.1M |
|
9
Intuitive Surgical
ISRG
$134B
| $47.8M | 2.75% |
+180,127
| New | +$43.9M |
|
10
Stryker
SYK
$130B
| $47.6M | 2.74% |
+194,707
| New | +$44.2M |
|
11
Boston Scientific
BSX
$71.5B
| $47.3M | 2.72% |
+1,021,516
| New | +$44.2M |
|
12
Pfizer
PFE
$153B
| $47M | 2.7% |
+917,358
| New | +$44M |
|
13
Novartis
NVS
$297B
| $46.9M | 2.7% |
+517,129
| New | +$43.6M |
|
14
Danaher
DHR
$144B
| $46.5M | 2.67% |
+197,663
| New | +$45.8M |
|
15
Eli Lilly
LLY
$1.06T
| $46.3M | 2.66% |
+126,548
| New | +$44.9M |
|
16
Amgen
AMGN
$222B
| $44.1M | 2.53% |
+167,861
| New | +$45M |
|
17
Regeneron Pharmaceuticals
REGN
$80.8B
| $42.9M | 2.47% |
+59,463
| New | +$43.9M |
|
18
Bristol-Myers Squibb
BMY
$132B
| $42.3M | 2.43% |
+588,165
| New | +$44.3M |
|
19
Elevance Health
ELV
$85.5B
| $41.7M | 2.4% |
+81,386
| New | +$41.3M |
|
20
Medtronic
MDT
$112B
| $39.4M | 2.27% |
+507,240
| New | +$41.1M |
|
21
Visa
V
$677B
| $29.7M | 1.71% |
+142,783
| New | +$28.8M |
|
22
Microsoft
MSFT
$3.71T
| $28.5M | 1.64% |
+118,804
| New | +$28.5M |
|
23
Accenture
ACN
$108B
| $27.1M | 1.56% |
+101,708
| New | +$28.1M |
|
24
Intel
INTC
$513B
| $27M | 1.55% |
+1,020,125
| New | +$28.3M |
|
25
Alphabet (Google) Class A
GOOGL
$4.33T
| $25M | 1.44% |
+283,300
| New | +$26.9M |
|
Similar funds
EMPI
EAM
JWBC
AA
RCG
CIS
AAM
DTC
Harvest Portfolios Group's Q4 2022 Portfolio in Review
Q4 2022 is the first quarter with a 13F filing on record for Harvest Portfolios Group, which disclosed 178 positions worth $1.74B. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Johnson & Johnson: 346,707 shares worth $61.2M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, followed by Technology and Financials.
- Harvest Portfolios Group's largest Q4 2022 buy was Johnson & Johnson: 346,707 shares worth $61.2M.
- Harvest Portfolios Group's ten largest holdings make up 29% of its $1.74B portfolio in Q4 2022.
- Harvest Portfolios Group disclosed 178 positions in Q4 2022, its first 13F filing on record.
Based on Harvest Portfolios Group's 13F filing for Q4 2022, filed 14 Feb 2023.